Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award
Prof. Dr. Takuma Hayashi, National Hospital Organization Kyoto Medical Center, Japan
Prof. Dr. Takuma Hayashi is a renowned Japanese physician-scientist specializing in gynecologic oncology. He earned his PhD from the University of Tokyo and trained at MIT’s Whitehead Institute
, contributing to Nobel-linked research. Currently a professor at Shinshu University and Section Head at Kyoto Medical Center
, his groundbreaking work on uterine leiomyosarcoma (LMS) identified LMP2 deficiency as a key biomarker
. Through precision medicine and genomic profiling
, his research has significantly advanced diagnostics and treatment strategies for LMS. With over 30 years of funded research, Dr. Hayashi is globally recognized for revolutionizing women’s cancer care.
Publication Profile
Education
Prof. Dr. Takuma Hayashi is a distinguished physician-scientist known for bridging fundamental cancer research with clinical applications. He is a Professor at Shinshu University Graduate School of Medicine and Section Head at Japan’s National Hospital Organization Kyoto Medical Center.
Dr. Hayashi earned his PhD from the University of Tokyo and completed postdoctoral training at MIT’s Whitehead Institute under Dr. Rick A. Young.
He contributed to Nobel Prize-linked AIDS vaccine research with Dr. David Baltimore. With over 30 years of NIH and JSPS funding, his work focuses on molecular research in uterine leiomyosarcoma and ovarian cancer, collaborating with Nobel Laureate Dr. Susumu Tonegawa.
Experience
Prof. Dr. Takuma Hayashi has pioneered precision medicine breakthroughs in uterine leiomyosarcoma (LMS) treatment. His team used cancer genome panel testing to tailor therapies based on each tumor’s unique genetics. For example, immunotherapy with pembrolizumab led to significant tumor regression, while targeted treatment with pazopanib stabilized disease for months.
Dr. Hayashi’s background from the University of Tokyo and MIT supports his innovative approach.
His ongoing goals include developing diagnostics, launching clinical trials, expanding global collaboration, and improving patient access to genomic profiling.
His work offers new hope for women facing this aggressive cancer.
Research Focus
Prof. Dr. Takuma Hayashi’s research primarily focuses on molecular oncology and infectious diseases, particularly cancer biomarkers and viral infections. His work on uterine leiomyosarcoma involves discovering key diagnostic biomarkers like LMP2 to improve early detection and treatment strategies in aggressive cancers.
Additionally, Dr. Hayashi explores infectious diseases such as avian influenza and COVID-19, emphasizing the One Health approach to prevent viral spread between animals and humans.
His interdisciplinary research bridges cancer biology, immunology, and public health, aiming to develop precision medicine therapies and enhance global disease control efforts.
Publication Top Notes
THE ROLE OF LIVE BIRD MARKETS SHOULD BE EMPHASIZED IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA INFECTIONS
THE IMPORTANCE OF ONE HEALTH IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA/H5N1
Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with Gastric Cancer Associated with Hereditary Breast and Ovarian Cancer
DEVELOPMENT OF ENDOSALPINGIOSIS IN PATIENTS WITH A HISTORY OF BREAST CANCER
High Transferability of Neutralizing Antibodies against SARS-CoV-2 to Umbilical Cord Blood in Pregnant Women Vaccinated with BNT162b2 XBB.1.5: A Retrospective Cohort Study
POTENTIAL DIAGNOSTIC BIOMARKERS FOR HUMAN MESENCHYMAL TUMORS, ESPECIALLY LMP2/Β1I AND CYCLIN E1/MIB1 DIFFERENTIAL EXPRESSION: PRUM-IBIO STUDY